Lipid and lipoprotein responses to oral combined hormone replacement therapy in normolipemic obese women with controlled type 2 diabetes mellitus.
This study investigated the effects of oral combined hormone replacement therapy (OCHRT) on lipid concentrations and subpopulation distribution of lipoproteins in nine postmenopausal women with type 2 diabetes mellitus and moderate glycemic control. After 16 weeks of continuous daily therapy of conjugated estrogens 0.625 mg and medroxyprogesterone 2.5 mg, the mean concentration of high-density lipoprotein (HDL) cholesterol showed a statistically significant increase of 16.7%, predominantly in the HDL2 subfraction. No statistically significant changes in mean concentrations of total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, very low-density lipoprotein (VLDL) triglycerides, apolipoprotein A1, or apolipoprotein B were evident. Likewise, no changes were found in the average diameter of VLDL, LDL, or HDL particles; triglyceride concentrations of VLDL subfractions; cholesterol concentrations of LDL subfractions; or chemical composition of plasma LDL. These findings lend further support to the use of OCHRT in postmenopausal women with diabetes to decrease their risk for coronary artery disease.
Lilley
S H
SH
Department of Family Medicine, East Carolina University School of Medicine, 600 Moye Blvd, Brody 4N-51, Greenville, NC 27858, USA.
Spivey
J M
JM
Vadlamudi
S
S
Otvos
J
J
Cummings
D M
DM
Barakat
H
H
D000284:Administration, Oral; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D015914:Estrogen Replacement Therapy; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D010316:Particle Size
D006442:Glycated Hemoglobin; D008055:Lipids; D008074:Lipoproteins